Emily Dykhuizen

Prof. Emily Dykhuizen

orcid

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 May 2013 in Nature
Verified
Journal Article
Open access
PDF file
EDEmily Dykhuizen
Emily Dykhuizen
DHDiana C. Hargreaves
Diana C. Hargreaves
EMErik L. Miller
Erik L. Miller
KCKairong Cui
Kairong Cui
Andrey KorshunovAndrey Korshunov
Andrey Korshunov
GCGerald R. Crabtree
Gerald R. Crabtree
Mutations in the subunits of BAF chromatin-remodelling complexes are frequently found in human cancer; here deletion of BAF subunits or expression of mutants of the ATPase subunit BRG1 attenuates genome-wide binding of topoisomerase IIα, resulting in tangled chromosomes, anaphase bridges and G2/M arrest. The multisubunit BAF chromatin-remodelling complex regulates gene expression, and mutations in its BRG1 subunit are common in certain cancers. Gerald Crabtree and colleagues show that in the absence of BRG1, or in the presence of BRG1 containing mutations found in medulloblastoma patients, chromosomes form anaphase bridges and cells undergo a G2/M arrest. They find that BAF interacts with topoisomerase IIα (TOP2A), an enzyme that decatenates replicated chromosomes during mitosis. Without the ATPase activity of BRG1, TOP2A cannot bind DNA, resulting in tangled chromosomes that are improperly segregated. These findings suggest that the prevention of DNA entanglement at mitosis by TOP2A requires BAF complexes and that this activity contributes to the role of BAF subunits as tumour suppressors. Recent exon-sequencing studies of human tumours have revealed that subunits of BAF (mammalian SWI/SNF) complexes are mutated in more than 20% of all human malignancies1,2, but the mechanisms involved in tumour suppression are unclear. BAF chromatin-remodelling complexes are polymorphic assemblies that use energy provided by ATP hydrolysis to regulate transcription through the control of chromatin structure3 and the placement of Polycomb repressive complex 2 (PRC2) across the genome4,5. Several proteins dedicated to this multisubunit complex, including BRG1 (also known as SMARCA4) and BAF250a (also known as ARID1A), are mutated at frequencies similar to those of recognized tumour suppressors. In particular, the core ATPase BRG1 is mutated in 5–10% of childhood medulloblastomas6,7,8,9 and more than 15% of Burkitt’s lymphomas10,11. Here we show a previously unknown function of BAF complexes in decatenating newly replicated sister chromatids, a requirement for proper chromosome segregation during mitosis. We find that deletion of Brg1 in mouse cells, as well as the expression of BRG1 point mutants identified in human tumours, leads to anaphase bridge formation (in which sister chromatids are linked by catenated strands of DNA) and a G2/M-phase block characteristic of the decatenation checkpoint. Endogenous BAF complexes interact directly with endogenous topoisomerase IIα (TOP2A) through BAF250a and are required for the binding of TOP2A to approximately 12,000 sites across the genome. Our results demonstrate that TOP2A chromatin binding is dependent on the ATPase activity of BRG1, which is compromised in oncogenic BRG1 mutants. These studies indicate that the ability of TOP2A to prevent DNA entanglement at mitosis requires BAF complexes and suggest that this activity contributes to the role of BAF subunits as tumour suppressors.

26 January 2007 in ACS Chemical Biology
Verified
Journal Article
Closed access
CCCoby B. Carlson
Coby B. Carlson
PMPatricia Mowery
Patricia Mowery
RORobert M. Owen
Robert M. Owen
EDEmily Dykhuizen
Emily Dykhuizen
LKLaura L. Kiessling
Laura L. Kiessling

1 March 2018 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
AAAktan Alpsoy
Aktan Alpsoy
EDEmily Dykhuizen
Emily Dykhuizen
The mammalian SWI/SNF chromatin remodeling complex is a heterogeneous collection of related protein complexes required for gene regulation and genome integrity. It contains a central ATPase (BRM or BRG1) and various combinations of 10-14 accessory subunits (BAFs for BRM/BRG1 Associated Factors). Two distinct complexes differing in size, BAF and the slightly larger Polybromo-BAF (PBAF), share many of the same core subunits but are differentiated primarily by having either AT-rich interaction domain 1A/B (ARID1A/B in BAF) or ARID2 (in PBAF). Using density gradient centrifugation and immunoprecipitation, we have identified and characterized a third and smaller SWI/SNF subcomplex. We termed this complex GBAF because it incorporates two mutually exclusive paralogs, glioma tumor suppressor candidate region gene 1 (GLTSCR1) or GLTSCR1-like (GLTSCR1L), instead of an ARID protein. In addition to GLTSCR1 or GLTSCR1L, the GBAF complex contains bromodomain-containing 9 (BRD9) and the BAF subunits BAF155, BAF60, SS18, BAF53a, and BRG1/BRM. We observed that GBAF does not contain the core BAF subunits BAF45, BAF47, or BAF57. Even without these subunits, GBAF displayed in vitro ATPase activity and bulk chromatin affinity comparable to those of BAF. GBAF associated with BRD4, but unlike BRD4, the GBAF component GLTSCR1 was not required for the viability of the LNCaP prostate cancer cell line. In contrast, GLTSCR1 or GLTSCR1L knockouts in the metastatic prostate cancer cell line PC3 resulted in loss in proliferation and colony-forming ability. Taken together, our results provide evidence for a compositionally novel SWI/SNF subcomplex with cell type–specific functions.

21 April 2016 in PLOS ONE
Verified
Journal Article
Open access
PDF file
BCBasudev Chowdhury
Basudev Chowdhury
EPElizabeth G Porter
Elizabeth G Porter
JSJane C Stewart
Jane C Stewart
CFChristina R Ferreira
Christina R Ferreira
MSMatthew J Schipma
Matthew J Schipma
EDEmily Dykhuizen
Emily Dykhuizen
Polybromo-1 (PBRM1) is a component of the PBAF (Polybromo-associated-BRG1- or BRM-associated factors) chromatin remodeling complex and is the second most frequently mutated gene in clear-cell renal cell Carcinoma (ccRCC). Mutation of PBRM1 is believed to be an early event in carcinogenesis, however its function as a tumor suppressor is not understood. In this study, we have employed Next Generation Sequencing to profile the differentially expressed genes upon PBRM1 re-expression in a cellular model of ccRCC. PBRM1 re-expression led to upregulation of genes involved in cellular adhesion, carbohydrate metabolism, apoptotic process and response to hypoxia, and a downregulation of genes involved in different stages of cell division. The decrease in cellular proliferation upon PBRM1 re-expression was confirmed, validating the functional role of PBRM1 as a tumor suppressor in a cell-based model. In addition, we identified a role for PBRM1 in regulating metabolic pathways known to be important for driving ccRCC, including the regulation of hypoxia response genes, PI3K signaling, glucose uptake, and cholesterol homeostasis. Of particular novelty is the identification of cell adhesion as a major downstream process uniquely regulated by PBRM1 expression. Cytoskeletal reorganization was induced upon PBRM1 reexpression as evidenced from the increase in the number of cells displaying cortical actin, a hallmark of epithelial cells. Genes involved in cell adhesion featured prominently in our transcriptional dataset and overlapped with genes uniquely regulated by PBRM1 in clinical specimens of ccRCC. Genes involved in cell adhesion serve as tumor suppressor and maybe involved in inhibiting cell migration. Here we report for the first time genes linked to cell adhesion serve as downstream targets of PBRM1, and hope to lay the foundation of future studies focusing on the role of chromatin remodelers in bringing about these alterations during malignancies.

1 May 2008 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
EDEmily Dykhuizen
Emily Dykhuizen
JMJohn F. May
John F. May
ATAimon Tongpenyai
Aimon Tongpenyai
LKLaura L. Kiessling
Laura L. Kiessling

21 December 2020 in Cancer Research
Verified
Journal Article
Open access
PDF file
AAAktan Alpsoy
Aktan Alpsoy
SUSagar Utturkar
Sagar Utturkar
BCBenjamin C. Carter
Benjamin C. Carter
ADAlisha Dhiman
Alisha Dhiman
STSandra E. Torregrosa-Allen
Sandra E. Torregrosa-Allen
EDEmily Dykhuizen
Emily Dykhuizen
Switch/sucrose-nonfermentable (SWI/SNF) chromatin-remodeling complexes are critical regulators of chromatin dynamics during transcription, DNA replication, and DNA repair. A recently identified SWI/SNF subcomplex termed GLTSCR1/1L-BAF (GBAF; or “noncanonical BAF”, ncBAF) uniquely contains bromodomain-containing protein BRD9 and glioma tumor suppressor candidate region 1 (GLTSCR1) or its paralog GLTSCR1-like (GLTSCR1L). Recent studies have identified a unique dependency on GBAF (ncBAF) complexes in synovial sarcoma and malignant rhabdoid tumors, both of which possess aberrations in canonical BAF (cBAF) and Polybromo-BAF (PBAF) complexes. Dependencies on GBAF in malignancies without SWI/SNF aberrations, however, are less defined. Here, we show that GBAF, particularly its BRD9 subunit, is required for the viability of prostate cancer cell lines in vitro and for optimal xenograft tumor growth in vivo. BRD9 interacts with androgen receptor (AR) and CCCTC-binding factor (CTCF), and modulates AR-dependent gene expression. The GBAF complex exhibits overlapping genome localization and transcriptional targets as bromodomain and extraterminal domain–containing (BET) proteins, which are established AR coregulators. Our results demonstrate that GBAF is critical for coordinating SWI/SNF–BET cooperation and uncover a new druggable target for AR-positive prostate cancers, including those resistant to androgen deprivation or antiandrogen therapies. Significance: Advanced prostate cancers resistant to androgen receptor antagonists are still susceptible to nontoxic BRD9 inhibitors, making them a promising alternative for halting AR signaling in progressed disease.